Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury
Cardiovascular Drugs and Therapy · 2026
DOI: 10.1007/s10557-024-07663-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2026. Verfasst von Nur Liyana Mohammed Yusof und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Myocytes, Cardiac, Myocardial Contraction, Myocardial Infarction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Malaysian Government.
Abstract (Originalsprache)
Purpose
Reperfusion of the ischaemic heart is essential to limit myocardial infarction. However, reperfusion can cause cardiomyocyte hypercontracture. Recently, cardiac myosin-targeted inhibitors (CMIs), such as Mavacamten (MYK-461) and Aficamten (CK-274), have been developed to treat patients with cardiac hypercontractility. These CMIs are well tolerated and safe in clinical trials. We hypothesised that, by limiting hypercontraction, CMIs may reduce hypercontracture and protect hearts in the setting of ischaemia and reperfusion (IR).
Methods
We investigated the ability of MYK-461 and CK-274 to inhibit hypercontracture of adult rat cardiomyocytes (ARVC) in vitro following ATP depletion. A suitable dose of CMIs for subsequent in vivo IR studies was identified using cardiac echocardiography of healthy male Sprague Dawley rats. Rats were anaesthetized and subject to coronary artery ligation for 30 min followed by 2 h of reperfusion. Prior to reperfusion, CMI or vehicle was administered intraperitoneally. Ischaemic preconditioning (IPC) was used as a positive control group. Infarct size was assessed by tetrazolium chloride staining and extent of hypercontracture was assessed by histological staining.
Results
Treatment with CMIs inhibited ARVC hypercontracture in vitro . MYK-461 (2 mg/kg) and CK-274 (0.5 mg/kg to 2 mg/kg) significantly reduced infarct size vs. vehicle. IR caused extensive contraction band necrosis, which was reduced significantly by IPC but not by CMIs, likely due to assay limitations. GDC-0326, an inhibitor of PI3Kα, abrogated CK-274-mediated protection following IR injury. GDC-0326 reduced phosphorylation of AKT when administered together with CK-274.
Conclusion
This study identifies CMIs as novel cardioprotective agents in the setting of IR injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
- Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.
- The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. s.davidson@ucl.ac.uk.
ORCID-Profile: Nur Liyana Mohammed Yusof, Derek M Yellon, Sean M Davidson
Förderung
- British Heart Foundation
- Malaysian Government
Zitieren
APA
Yusof, N. L. M., Yellon, D. M., & Davidson, S. M. (2026). Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07663-0
Vancouver
Yusof NLM, Yellon DM, Davidson SM. Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury. Cardiovascular Drugs and Therapy. 2026. doi:10.1007/s10557-024-07663-0
BibTeX
@article{Yusof2026,
author = {Yusof, Nur Liyana Mohammed and Yellon, Derek M and Davidson, Sean M},
title = {Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury},
journal = {Cardiovascular Drugs and Therapy},
year = {2026},
doi = {10.1007/s10557-024-07663-0}
}
EUVIMED